Elicio Therapeutics, Inc. Board of Directors
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph nodetargeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company is also developing ELI-007, a multivalent lymph nodetargeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph nodetargeted AMP peptide vaccine to target p53 hotspot mutations. The company is headquartered in Boston, Massachusetts.

Mr. Robert T. Connelly
CEO, President, Principal Accounting Officer, Principal Financial Officer & Director
Prof. Darrell J. Irvine Ph.D.
Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board
Dr. Christopher M. Haqq M.D., Ph.D.
Executive VP, Head of Research & Development and Chief Medical Officer
Leaving Board of Directors Review
Your about to visit the following url
Invalid URL
Loading...
Comments
Comment created.